BioGend Therapeutics Statistics

Total Valuation

TPEX:6733 has a market cap or net worth of TWD 4.54 billion. The enterprise value is 4.00 billion.

Market Cap	4.54B
Enterprise Value	4.00B

Important Dates

The last earnings date was Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

TPEX:6733 has 124.26 million shares outstanding. The number of shares has decreased by -0.48% in one year.

Current Share Class	124.26M
Shares Outstanding	124.26M
Shares Change (YoY)	-0.48%
Shares Change (QoQ)	-1.76%
Owned by Insiders (%)	4.11%
Owned by Institutions (%)	2.56%
Float	75.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.29
PB Ratio	5.77
P/TBV Ratio	6.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-31.44
EV / Sales	20.49
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-52.88

Financial Position

The company has a current ratio of 21.53, with a Debt / Equity ratio of 0.01.

Current Ratio	21.53
Quick Ratio	19.98
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.10
Interest Coverage	-734.06

Financial Efficiency

Return on equity (ROE) is -15.13% and return on invested capital (ROIC) is -9.58%.

Return on Equity (ROE)	-15.13%
Return on Assets (ROA)	-9.04%
Return on Invested Capital (ROIC)	-9.58%
Return on Capital Employed (ROCE)	-16.14%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.21
Inventory Turnover	3.01

Taxes

Income Tax	-8.31M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.60% in the last 52 weeks. The beta is 0.09, so TPEX:6733's price volatility has been lower than the market average.

Beta (5Y)	0.09
52-Week Price Change	+9.60%
50-Day Moving Average	30.16
200-Day Moving Average	31.92
Relative Strength Index (RSI)	84.59
Average Volume (20 Days)	241,647

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TPEX:6733 had revenue of TWD 195.02 million and -127.10 million in losses. Loss per share was -1.04.

Revenue	195.02M
Gross Profit	146.01M
Operating Income	-131.40M
Pretax Income	-136.56M
Net Income	-127.10M
EBITDA	-85.07M
EBIT	-131.40M
Loss Per Share	-1.04

Full Income Statement

Balance Sheet

The company has 575.56 million in cash and 7.58 million in debt, giving a net cash position of 567.98 million or 4.57 per share.

Cash & Cash Equivalents	575.56M
Total Debt	7.58M
Net Cash	567.98M
Net Cash Per Share	4.57
Equity (Book Value)	786.82M
Book Value Per Share	6.26
Working Capital	644.34M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -75.02 million and capital expenditures -560,000, giving a free cash flow of -75.58 million.

Operating Cash Flow	-75.02M
Capital Expenditures	-560,000
Free Cash Flow	-75.58M
FCF Per Share	-0.61

Full Cash Flow Statement

Margins

Gross margin is 74.87%, with operating and profit margins of -67.38% and -65.18%.

Gross Margin	74.87%
Operating Margin	-67.38%
Pretax Margin	-70.03%
Profit Margin	-65.18%
EBITDA Margin	-43.62%
EBIT Margin	-67.38%
FCF Margin	n/a

Dividends & Yields

TPEX:6733 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.48%
Shareholder Yield	n/a
Earnings Yield	-2.80%
FCF Yield	-1.66%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TPEX:6733 has an Altman Z-Score of 42.92 and a Piotroski F-Score of 2.

Altman Z-Score	42.92
Piotroski F-Score	2